Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is conducted to investigate the pharmacokinetics of Doripenem during CVVHDF (Continuous venovenous hemodiafiltration), MARS (Molecular Adsorbent Recirculating System) and intermittent hemodialysis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pharmacokinetic profiling in Hemodialysis | Experimental | Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn. |
|
| Pharmacokinetic profiling in CVVH | Experimental | Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn. |
|
| Pharmacokinetic profiling in MARS | Experimental | Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pharmacokinetic profiling | Other | Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial. |
| Measure | Description | Time Frame |
|---|---|---|
| Influence of organ replacement therapy on area under curve of doripenem serum concentration | Pharmacokinetic samples are drawn from each patient during the trial. Analysis by HPLC will be conducted after the end of the trial. | day 15 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University of Vienna | Vienna | 1090 | Austria |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29530855 | Derived | Vossen MG, Ehmann L, Pferschy S, Maier-Salamon A, Haidinger M, Weiser C, Wenisch JM, Saria K, Kajahn C, Jilch S, Lemmerer R, Becede M, Zeitlinger M, Kloft C, Jager W, Thalhammer F. Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02430-17. doi: 10.1128/AAC.02430-17. Print 2018 May. | |
| 26711775 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Derived |
| Vossen MG, Wenisch JM, Maier-Salamon A, Fritsch A, Saria K, Zuba C, Jilch S, Lemmerer R, Unger M, Jaehde U, Jager W, Thalhammer F. Doripenem Treatment during Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1687-94. doi: 10.1128/AAC.01801-15. |